Spruce Biosciences Inc. (SPRB) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    Spruce Biosciences Inc.

    NASDAQ: SPRB · Real-Time Price · USD
    8.55
    -1.15 (-11.86%)
    At close: Sep 11, 2025, 9:36 AM
    8.55
    0.00%
    Pre-market: Sep 11, 2025, 09:36 AM EDT

    Spruce Biosciences Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 4.91M 10.09M n/a n/a
    Cost of Revenue
    		 n/a n/a 429K 381K
    Gross Profit
    		 4.91M 10.09M -429K -381K
    Operating Income
    		 -56.15M -51.99M -47.28M -42.07M
    Interest Income
    		 3.42M 4.56M 1.52M 119K
    Pretax Income
    		 -53.04M -47.92M -46.18M -42.29M
    Net Income
    		 -53.04M -47.92M -46.18M -42.69M
    Selling & General & Admin
    		 14.64M 12.65M 12.09M 11.37M
    Research & Development
    		 46.42M 49.43M 35.2M 30.7M
    Other Expenses
    		 n/a n/a n/a 119K
    Operating Expenses
    		 61.06M 62.08M 47.28M 42.07M
    Interest Expense
    		 307K 483K 420K 345K
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 61.06M 62.08M 47.28M 42.07M
    Income Tax Expense
    		 n/a n/a n/a 396K
    Shares Outstanding (Basic)
    		 536.44K 500.63K 611.71K 607.4K
    Shares Outstanding (Diluted)
    		 536.44K 500.63K 611.71K 607.4K
    EPS (Basic)
    		 -96.75 -93 -72 -68.25
    EPS (Diluted)
    		 -96.75 -93 -72 -68.25
    EBITDA
    		 -52.68M -47.37M -45.33M -41.57M
    EBIT
    		 -52.73M -47.44M -45.76M -41.95M
    Depreciation & Amortization
    		 46K 70K 429K 381K

    Add to Watchlist